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Abstract  
Background: 
Few studies have determined the very long-term mortality risks in adult and childhood-
diagnosed coeliac disease.  
 
Objective: 
We quantified mortality risks in coeliac disease and determined whether age at 
diagnosis, or time following diagnosis modified these risks. 
 
Methods: 
Standardised mortality ratios (SMRs) were determined using data from a cohort of 602 
coeliac patients assembled between 1979 and 1983 from Lothian, Scotland, and 
followed up from 1970 until 2016.  
 
Results: 
All-cause mortality was 43% higher than in the general population. Excess deaths were 
primarily from haematological malignancies (SMR, 4.77) and external causes (SMR, 
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2.62) in adult and childhood-diagnosed cases respectively. Mortality risks declined 
steadily with time in adult-diagnosed cases (SMR, 4.85 in first year compared to 0.97, 
25 years post-diagnosis). Beyond 15 years, this group had a significantly reduced risk of 
any malignancy (SMR, 0.57 [95% CI: 0.33-0.92]). In contrast, for childhood-diagnosed 
cases an increased risk existed beyond 25 years (SMR, 2.24). 
 
Conclusions: 
Adult-diagnosed coeliac patients have a temporary increased mortality risk mainly from 
malignant lymphomas and a decreased risk of any malignancy beyond 15 years post-
diagnosis. In contrast, childhood-diagnosed cases are at an increased risk of mortality 
mainly from external causes, and have long-term mortality risks that requires further 
investigation. 
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Key summary 
Established knowledge on subject 
 Coeliac disease is associated with increased risk of mortality mainly from 
specific malignancies. 
 Increased mortality risks in coeliac disease are greatest during the first few years 
of diagnosis. 
Significant findings of current study 
 Adult-diagnosed coeliac disease patients have no significant excess risk of all-
cause mortality beyond 25 years after diagnosis, with the confidence intervals 
around the standardised mortality ratio excluding a greater than 25% increase. 
 Adult-diagnosed coeliac disease patients have a reduced risk of death from any 
malignancy more than 15 years after diagnosis. 
 Childhood-diagnosed coeliac disease patients have a long-term mortality risk 
that merits further investigation.  
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Introduction  
Coeliac disease (CD) patients are reported to have a higher mortality risk than the 
general population, although the reported magnitude of this increase in risk varies 
widely.1-8 There is consensus that these increased mortality risks are observed 
predominantly within a few years of diagnosis (1-4 years).1,4-6 Owing to limited follow-
up, the majority of studies have not been able to assess whether these risks persist for 
long periods (>20 years) after diagnosis. Furthermore, studies have focused entirely on 
adults1,4 or included considerably more individuals diagnosed in adulthood (>85%) than 
in childhood,3,6,9 with many1,3,4 but not all9 reporting them to be at an increased risk of 
mortality primarily from lymphatic malignancies. Only a few studies3,5 have included 
children or assessed mortality risks in patients diagnosed in childhood, and these have 
been limited by short follow-up times5 and a focus on inpatients,3 who are more likely 
to have worse outcomes. 
To our knowledge, the first study to have sufficient follow-up time to assess the 
difference in mortality risks between childhood and adulthood-diagnosed CD and the 
long-term trends in these risks was that carried out by Solaymani-Dodaran et al.10 on a 
cohort of CD patients followed up from 1970 to 2004 (Lothian cohort). Their finding of 
an increase in long-term mortality in childhood-diagnosed cases, including an excess 
mortality particularly from external causes has not been corroborated. Evidently, further 
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research is needed to ascertain the magnitude of mortality risks associated with the 
disease and the very long-term (>20 years) changes in these risks. An additional 10 
years of mortality data on the Lothian cohort enabled us to explore mortality risks 
further, and with greater statistical power; we aimed to quantify the overall and cause-
specific mortality risks in adult and childhood-diagnosed CD, and determine whether 
these risks persist more than 25 years following diagnosis.  
 
Methods 
Study participants 
Our cohort consisted of CD cases sourced from the Lothian region of Scotland between 
1979 and 1983. The Lothian region comprises the administrative districts of West, East 
and Mid-Lothian and the City of Edinburgh. Its total population in 1979 was estimated 
at 764,688.11 Current population estimates indicate little variation in the population 
statistics, the most recent population estimate being 880,000.12 
Participants were predominantly resident in the City of Edinburgh, and were 
identified through: diagnostic records of gastrointestinal units; existing histopathology 
records; 1961-1977 CD admissions recorded in the Scottish Hospital Inpatient 
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Statistics; a postal survey of 440 general practitioners; and the region’s CD patient 
support group. Further details of the participants have been published elsewhere.11,13 We 
included all participants with at least one small bowel biopsy showing abnormalities 
typical of CD, some of which were confirmed by a second small bowel biopsy 
following a gluten withdrawal or gluten challenge (i.e. confirmed CD) and some of 
which were not (i.e. probable CD). Participants were further classified during enrolment 
into: childhood-diagnosed (patients diagnosed prior to their 15th birthday) and 
adulthood-diagnosed (patients diagnosed on or after their 15th birthday) CD cases.11 
Study design 
Follow-up commenced on the later of January 1, 1970 (date of first active tracking of 
cohort) or the date of clinical diagnosis until the earliest of loss to follow-up, death, or 
October 20, 2016. Given that participants were recruited into the study between 1979 
and 1983, follow-up prior to 1979 was retrospective.  
Cohort mortality data 
Following an initial search of Scottish National Death Records, participants identified to 
be alive were flagged in the National Health Service Central Register. Upon death, 
copies of their death certificates were sent to the study team, who linked information on 
the underlying causes of death to the cohort participants. The underlying causes of death 
8 
 
were coded using the 8th-10th revisions of the International Classification of Diseases 
(ICD). 
Population mortality data 
Mortality rates were determined by applying population mortality estimates for the 
Lothian region obtained from the National Records of Scotland12,14 for the years 1974-
2016. Population mortality estimates for the years 1970-1973 and cause-specific death 
estimates for 2016 were unavailable, and were extrapolated from the average mortality 
estimates for the periods of 1974-1976 and 2013-2015 respectively. 
Statistical analysis 
Overall and cause-specific mortality  
We calculated overall standardised mortality ratios (SMRs) and their 95% confidence 
intervals (CIs) for the total person-years of follow-up using indirect standardisation, by 
estimating the number of deaths expected in this amount of person-time when age (5-
year bands), gender and year specific mortality rates for the Lothian region were applied 
to our cohort. We then determined cause-specific SMRs for causes of death where we 
had population data (appendix), using the same approach. Overall and cause-specific 
SMRs were calculated for the whole cohort and separately for adult and childhood-
diagnosed cases. 
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Mortality risks by time since diagnosis 
To determine whether mortality risks in the cohort were modified by the length of time 
following diagnosis, we calculated overall SMRs for the following times: first year of 
diagnosis, 0-4 years, 5-9 years, 10-14 years, 15-24 years and 25 years or more post-
diagnosis and cause-specific SMRs for the following times: < 15 years following 
diagnosis and ≥ 15 years following diagnosis. 
Sensitivity analysis 
To determine whether conclusions made were dependent on whether or not CD in the 
patient had been confirmed, we carried out a sensitivity analysis by repeating the 
analyses in participants with confirmed CD only.  
All analyses were carried out using Stata v. 14.2.  
 
Results 
Cohort Characteristics 
Our cohort consisted of 602 participants diagnosed with CD between 1943 and 1983 
(Table 1) (we excluded 23 participants from the original cohort of 625, who had died 
before our study start date). Of these, 73% had their diagnosis confirmed by one or 
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more biopsies following gluten withdrawal or a gluten challenge. 318 (53%) 
participants were diagnosed as adults at a mean age of 45 years, and 284 (47%) were 
diagnosed as children at a median age of 1.58 years. Participants contributed to a total 
follow-up of 19,071 person-years, with childhood-diagnosed cases accounting for a 
greater percentage of the follow-up time (60%). 205 (64%) adult-diagnosed cases had 
died before the end of the study period compared with 32 (11%) childhood-diagnosed 
cases. 
Overall and cause-specific mortality risks 
The causes of deaths analysed and the average ages at which participants died from 
these causes are presented in Figures 1 and 2 respectively. We observed an excess of 
70.8 deaths (237 observed deaths, 166.2 expected deaths) from all causes in the cohort 
during the entire study period (Table 2). This represents a relative excess mortality risk 
of 43% in the cohort compared to the general Lothian population (SMR=1.43; 95% CI 
1.25-1.62). Participants diagnosed in childhood had more than double the risk of dying 
(SMR=2.11; 95% CI 1.44-2.97) compared with a 36% increase in risk in those 
diagnosed in adulthood (SMR=1.36; 95% CI 1.18-1.56). 
The overall excess mortality was accounted for at least in part by lymphatic and 
haematopoietic tissue (haematological) malignancies in adulthood-diagnosed cases, and 
by accidents, suicides and violence (external causes) in childhood-diagnosed cases 
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(Figure 1). In adult cases there were 13 haematological malignancies (all of which were 
specifically lymphoma), compared with 2.7 expected, resulting in an SMR of 4.77 (95% 
CI 2.54-8.16). Childhood-diagnosed cases had an increase in risk of death from external 
causes (SMR=2.62; 95% CI 1.05-5.40), haematological malignancies (SMR=8.03; 95% 
CI 1.66-23) and cerebrovascular diseases (SMR=4.42; 95% CI 0.53-16), although the 
last of these was not statistically significant. 
Mortality risks by time since diagnosis 
Overall, mortality risks for the entire cohort declined gradually over time (Table 3).  
This decreasing trend was driven by the results in adult-diagnosed cases. The highest 
mortality risk for this group was observed in the year following diagnosis (SMR=4.85; 
95% CI 2.42-8.68). Within 5 to 9 years post-diagnosis, the excess risks had decreased to 
49% (SMR=1.49; 95% CI 0.97-2.18).  Beyond 25 years after diagnosis, adulthood-
diagnosed CD patients had no significant excess risk, with the confidence intervals 
around the SMR excluding a greater than 25% increase (SMR=0.97, 95% CI 0.74-1.24). 
Our analysis of childhood-diagnosed cases was somewhat hampered by a small number 
of expected deaths during the first 24 years following diagnosis. However, beyond 25 
years after diagnosis, those diagnosed in childhood had more than double the mortality 
risk (SMR=2.24; 95% CI 1.45-3.30).  
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When cause-specific deaths were analysed in the whole cohort, it appeared that 
most of the excess deaths from the different causes had been accrued during the first 15 
years following diagnosis (Table 4). Among adult-diagnosed cases, there were 
significantly raised mortality risks in the first 15 years for all malignancy as well as for 
digestive cancers and haematological malignancies specifically. In contrast, beyond 15 
years there was a modest but statistically significant decreased risk of mortality from 
any malignancy (SMR=0.57; 95% CI 0.33-0.92). In childhood-diagnosed cases, the 
majority of deaths in the first 15 years were from external causes (SMR=4.89; 95% CI 
1.01-14). Beyond 15 years, the increased risks from these causes persisted, although 
lower than before (SMR=1.95; 95% CI 0.53-4.98). For this group, increased mortality 
beyond 15 years of diagnosis was strongest for haematological malignancies 
(SMR=9.44; 95% CI 1.95-28). 
Sensitivity analysis 
Restricting the analyses to confirmed cases did not produce any substantial differences 
in the estimates obtained (data not shown). We observed a similar pattern of higher 
mortality risks in childhood-diagnosed cases, as well as a decreasing trend in mortality 
risks with increasing time following diagnosis.  
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Discussion 
Key Findings 
People diagnosed with CD were at a 43% increased risk of mortality compared to the 
general population. The largest relative risks of death were from haematological 
malignancies (>90% of which were specifically lymphoma) in both adult and 
childhood-diagnosed cases. Mortality risks declined steadily with time since diagnosis, 
particularly in the adulthood-diagnosed cases. For these, we observed a lower than 
expected risk of mortality from all malignancies after the first 15 years of diagnosis. We 
did not have sufficient follow-up at ages where mortality is expected to be high in the 
childhood-diagnosed cases to be able to make robust conclusions. We are nevertheless 
confident that beyond 25 years post-diagnosis, CD patients diagnosed as adults are no 
longer at a higher risk of mortality compared to the general population.  
Strengths and Limitations 
Our study can boast a number of strengths, one of them being that it was population-
based and therefore not prone to selection bias. Another strength is the use of the 
generally accepted gold standard15 of biopsies as a means of confirmation of CD. By 
using death certificates to ascertain the underlying causes of death, we have ensured a 
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uniform quality of recording of causes of death in the cohort and the general population 
to which it was compared. We also have long follow-up, allowing us to assess longer-
term risks, something impossible for earlier studies.  
Supposing that CD truly raises mortality risks, then our estimates may have been 
underestimated by the inclusion of probable cases, if many of these did not indeed have 
CD (non-differential misclassification). In this instance, restricting the analyses to 
confirmed cases would have resulted in higher mortality estimates, at the cost of wider 
confidence intervals.  However, when we restricted the analyses to confirmed cases, we 
observed slightly lower mortality risks and similar trends in all-cause and cause-specific 
mortality, implying that our probable cases were likely to be true CD cases. Given that 
over 70% of our cases were confirmed, we are quite confident that the inclusion of 
probable cases did not affect our results substantially.  
There were other potential limitations. First, around 23% of the study 
participants lived outside the Lothian region (Fife or the Scottish borders) when 
diagnosed with CD.11 However, the demographic characteristics and mortality pattern of 
people living in Fife and the Scottish borders are generally similar to that of people in 
the Lothian region.16 Hence, we do not believe there are significant differences in the 
characteristics of the participants living within and outside the Lothian region to have 
rendered the population data used inappropriate. Second, we were unable to adjust for 
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the effect of certain factors such as socio-economic status, smoking, compliance with 
gluten-free diets (GFDs), body mass index (BMI), existence of co-morbidities, etc., 
which may be associated with high mortality risks. Previous studies, however, have 
found that adjusting for BMI, smoking6 and education5 did not remove the effect. Third, 
approximately half of the deaths in the cohort were from causes that we did not have 
population data on. We are therefore unable to speculate as to whether people with CD 
have different mortality risks from causes of death that we have not analysed.  
Other Studies 
Overall and cause-specific mortality 
The 43% raised mortality risk observed is much lower than most of the earlier reports1,4 
and more in agreement with recent studies,5,6 which have reported modest increases (30-
40%) in mortality risks in CD patients. This lends support to the findings of decreased 
mortality risks with increasing length of time following diagnosis,4-6 as our current 
analysis was based on follow-up data more than 15 years following diagnoses in most 
cases.  
We have just a few studies with which to compare our findings of higher risks in 
childhood than adulthood-diagnosed cases. While two studies3,5 have similarly reported 
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high risks in children, they either included young adults5 or had a shorter follow-up 
time.3 
Our finding of excess risks of death from malignant lymphomas in adult and 
childhood-diagnosed CD is consistent with other studies1,3,4,7 and our previous 
observation from this cohort that malignancy itself was raised in CD patients,17 a 
finding not supported by all previous research.18 Previous research has highlighted a 
reduced risk of breast cancer in CD patients,6,9 however, with only small numbers of 
deaths (<5) we were unable to say whether this extends to mortality from breast cancer. 
The observed excess deaths in childhood-diagnosed cases from external causes 
is consistent with prior publications from this cohort10,11 and reports of causes of death 
in children in the UK and worldwide.19 However, it is unclear why childhood-diagnosed 
CD patients would have significantly more of such deaths than the general population. 
According to Cinquetti et al.20 the acceptance of GFDs in children and adolescents can 
be associated with adverse psychological effects such as depression and anxiety. In 
addition, there is evidence that hypervigilance to GFDs may have a negative impact on 
quality of life.21 This may therefore make such individuals more inclined to intentional 
self-harm; however, this reasoning is speculative and further research is needed.  
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Mortality risks with time following diagnosis 
Similar to most studies,1,4,5,11 we have confirmed that the mortality risks in CD patients 
are greatest during the first few years after diagnosis. It is plausible that at the time of 
diagnosis, patients in our cohort (all of whom were diagnosed prior to 1984) were more 
symptomatic and presented with more severe forms of the disease, as has been 
hypothesized to be the case with patients diagnosed in the pre-serological era.8,22 This 
coincides with the recognition that diagnosis at this time was more difficult than what it 
has become with serology and endoscopic biopsy. This is evidenced from co-existing 
symptoms at the time of diagnosis among the present cohort.23 Another possible 
explanation is that the cases may have presented with illnesses other than CD, leading to 
an ascertainment bias with respect to CD diagnosis.  
Alternatively, it could be argued that CD patients adopt healthier lifestyles after 
their diagnoses and are therefore less likely to have higher mortality risks than before. 
As reported in some studies, CD patients are generally less likely than the general 
population to smoke or be obese6 and also, they have lower fat intake and better 
cholesterol profiles,24,25 all of which are associated with lower mortality risks. 
The reduction in all malignancies in adult cases 15 years following diagnosis is 
an interesting finding which needs further exploration through research. Few 
studies9,17,26 have reported a decrease in the incidence of malignancies in CD 10 years or 
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more following diagnoses, but we are not aware of any study, that corroborates our 
finding of decreased mortality risk from these causes 15 years after diagnosis. The 
results may have been driven by a combination of breast cancer and other cancers which 
share similar biological properties with breast and lung cancers, which some studies 
have shown CD patients to be protected from.6,9 Understanding the mechanism of 
protection of these cancers could provide valuable information on the treatment of 
cancers in the general population. 
The persistent increase in mortality risks in childhood-diagnosed cases more 
than 25 years after diagnosis is consistent with the earlier report on the cohort,10 and 
requires further investigation. A longer follow-up of these cases will enable a better 
assessment of the risks from diseases that occur in later years in life but this will 
necessitate several additional decades of follow-up of this cohort for us to be able to 
estimate these risks with sufficient precision. Therefore, retrospectively collected data 
available from people with childhood-diagnosed CD in the distant past is likely to offer 
our best hope of realising this. 
Mortality risks in the Lothian cohort over time 
A summary of key findings from all mortality follow-up of the Lothian cohort is 
provided in Table 5. 
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Conclusion 
Our study indicates that individuals with CD are at a modestly increased risk of 
mortality compared to the general population. The increased risk, primarily from 
malignant lymphomas are only temporary in adults and generally decline in the long-
term. The increased risk of death from external causes in childhood-diagnosed cases we 
highlighted in our previous report persisted with this longer-term follow-up and should 
form the focus of further research.  
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Figure legends 
Figure 1: Proportion of excess deaths from analysed causes 
Causes of death analysed in the cohort and the percentage of excess deaths from each of 
these causes, calculated as number of excess deaths from specific cause/total number of 
excess deaths x 100%. Definition of symbols used: *Significant number of excess deaths. 
 
Figure 2:  Average ages at death from specific causes 
Average age of death among participants who died by cause of death. 
 


Table 1: Cohort characteristics 
 
 
Age  at diagnosis  
 
Characteristic 
< 15 years 
(N= 284 ) 
≥ 15 years 
(N= 318) 
Total 
(N=602) 
Number of participants, n (%) 
   Male 129 (45.42) 105 (33.02) 234 (38.87) 
Female 155 (54.58) 213 (66.98) 368 (61.13) 
    Diagnosis, n (%) 
   Confirmed 197 (69.37) 242 (76.10) 439 (72.92) 
Probable   87 (30.63) 76 (23.90) 163 (27.08) 
    Age group at diagnosis (years), n (%) 
0-4 223 (78.52) - 223 (37.04) 
5-9   46 (16.20) - 46 (7.64) 
9-14  15 (5.28) - 15 (2.49) 
15-24 - 35 (11.01) 35 (5.81) 
25-34 - 63(19.81) 63(10.47) 
35-44 - 60 (18.87) 60 (9.97) 
45-54 - 58 (18.24) 58 (9.63) 
55-64 - 71 (22.33) 71 (11.79) 
65-74 - 27 (8.49) 27 (4.49) 
75-84 - 4 (1.26) 4 (0.66) 
    
Age at diagnosis (years) 
   Mean ± SD 2.97 ± 3.14 44.99 ± 15.49 25.17 ± 23.92 
Median (IQR) 1.58 (0.91-4.21) 45.46 (31.75-58.50) 21.67 (1.67-46.82) 
    Year of diagnosis, n (%) 
Prior to 1970 135 (47.54) 93 (29.25) 228 (37.87) 
1970-1983 149 (52.46) 225 (70.75) 374 (62.13) 
    
Status at end of study§, n (%) 
   Dead 32 (11.27) 205 (64.47) 237  (39.37) 
Alive 228 (80.28) 97 (30.50) 325 (53.99) 
Censored‡ 24 (8.44) 16 (5.03) 40 (6.64) 
    Follow-up time (person-years) 
   Total 11500.79 7570.95 19071.74 
Mean follow-up ± SD (per person) 40.50 ± 9.87 23.81 ± 15.46 31.68 ± 15.54 
    
N, total number; n, number within category; SD, Standard deviation  
§End of study, 26th October, 2016 
‡ Censored, lost to follow up through emigration 
 
 Table 2: Overall and cause-specific standardized mortality ratios by age at diagnosis 
 
 
Age at diagnosis  
<15 years (N= 284)  ≥15 years (N= 318 )  Overall (N= 602) 
Cause of Death Obs Exp SMR (95%CI)  Obs Exp SMR (95%CI)  Obs Exp SMR (95%CI) 
All Cause 32 15.20 2.11 (1.44-2.97)† 
 
205 151.02 1.36 (1.18-1.56)† 
 
237 166.22 1.43 (1.25 - 1.62)† 
All malignancy 8 3.74 2.14 (0.92-4.21) 
 
50 41.57 1.20 (0.89-1.59) 
 
58 45.32 1.28 (0.97-1.65) 
Digestive cancer <5 * 0.00 (0.00-4.53) 
 
16 10.82 1.48 (0.85-2.40) 
 
16 11.63 1.38 (0.79-2.23) 
Malignant lymphoma <5 * 8.03 (1.66-23)† 
 
13 2.73 4.77 (2.54-8.16)† 
 
16 3.1 5.16 (2.95-8.38)† 
Breast Cancer <5 * 2.69 (0.07-15) 
 
<5 * 0.00 (0.00-2.76) 
 
<5 * 0.59 (0.01-3.26) 
Cerebrovascular disease <5 * 4.42 (0.53-16) 
 
25 19.43 1.29 (0.83-1.90) 
 
27 19.88 1.36 (0.90-1.98) 
Ischemic Heart Disease <5 * 0.00 (0.00-2.86) 
 
42 35.63 1.18 (0.85-1.59) 
 
42 36.92 1.14 (0.82-1.54) 
Accident, Suicide  
and Violence 7 2.67 2.62 (1.05-5.40)† 
 
<5 * 0.90 (0.24-2.30) 
 
11 7.13 1.54 (0.77-2.76) 
            
SMR, Standardized mortality ratio; CI, Confidence Interval; Obs, Observed deaths; Exp, Expected deaths; N, Number of participants 
  
* In order to minimize the risk of disclosure of the identity of individual study participants, we have adhered to the rule of thumb suggested by 
the Office for National Statistics of suppressing all cell frequencies where the observed cell frequency is less than 5 (“Review of the 
Dissemination of Health Statistics: Confidentiality Guidance: National Statistics; HMSO 2006”). 
† P<0.05 
 Table 3: Overall standardised mortality ratios by time since diagnosis 
 
 
Age  at diagnosis 
    
 
< 15 years (N= 284) 
 
≥ 15 years (N= 318) 
 
Total population (N= 602) 
Time since 
diagnosis Obs Exp  SMR (95% CI) 
 
Obs Exp  SMR (95% CI) 
 
Obs Exp  SMR (95% CI) 
first yr.  <5 *   0.00 (0.00, 9.39) 
 
11 2.27   4.85 (2.42, 8.68)† 
 
11 2.66 4.14 (2.06, 7.40)† 
1-4 yrs.  <5 *   0.00 (0.00, 2.87) 
 
27 10.74   2.51 (1.66, 3.66)† 
 
27 12.03 2.24 (1.48, 3.27)† 
5-9 yrs.  <5 * 11.22 (3.06, 29.00) † 
 
26 17.5   1.49 (0.97, 2.18) 
 
30 17.86 1.68 (1.13, 2.40)† 
10-14 yrs. <5 *    2.18 (0.06, 12.00) 
 
29 18.57   1.56 (1.05, 2.24)† 
 
30 19.03 1.58 (1.06, 2.25)† 
15-24 yrs. <5 *  1.31 (0.16, 4.73) 
 
50 37.93   1.32 (0.98, 1.74) 
 
52 39.45 1.32 (0.98, 1.72) 
25+ yrs. 25 11.18  2.24 (1.45, 3.30) † 
 
62 64.01   0.97 (0.74, 1.24) 
 
87 75.19 1.16 (0.93, 1.43) 
          
SMR, Standardised mortality ratio; CI, Confidence Interval; Obs, Observed deaths; Exp, Expected deaths; N, Number of participants; yr.(s), 
years 
* In order to minimize the risk of disclosure of the identity of individual study participants, we have adhered to the rule of thumb suggested by 
the Office for National Statistics of suppressing all cell frequencies where the observed cell frequency is less than 5 (“Review of the 
Dissemination of Health Statistics: Confidentiality Guidance: National Statistics; HMSO 2006”). 
† P<0.05 
 
 
 Table 4: Cause-specific standardised mortality ratios by time since diagnosis 
 
 Age at diagnosis   
 
<15 years (N= 284)  ≥15 years (N= 318)  Total population 
Period after diagnosis Obs Exp SMR (95%CI) 
 
Obs Exp SMR (95%CI) 
 Obs Exp SMR (95%CI) 
All malignancy 
   
 
   
    
< 15 years <5 * 0.00 (0.00-23)  34 13.47 2.53 (1.75-3.53) †  34 13.62 2.50 (1.73-3.49) † 
≥15 years 8 3.58 2.23 (0.96-4.40)  16 28.11 0.57 (0.33-0.92)†  24 31.69 0.76 (0.49-1.13) 
Digestive cancer 
< 15 years <5 * 0.00 (0.00-780)  12 3.62 3.31 (1.71-5.79) †  12 3.63 3.31 (1.71-5.78) † 
≥15 years <5 * 0.00 (0.00-4.56)  <5 * 0.56 (0.15-1.42)  <5 * 0.50 (0.14-1.28) 
Lymphatic and haematopoietic tissue malignancies 
< 15 years <5 * 0.00 (0.00 -66)  10 0.77 13.04 (6.25-24) †  10 0.82 12.15 (5.83-22) † 
≥15 years <5 * 9.44 (1.95-28) †  <5 * 1.53 (0.32-4.48)  6 2.28 2.64 (0.97-5.74) 
Cerebrovascular disease 
< 15 years <5 * 0.00 (0.00-260)  8 6.20 1.29 (0.56-2.54)  8 6.21 1.29 (0.56-2.54) 
 ≥15 years <5 * 4.56 (0.55-16)  17 13.23 1.29 (0.75-2.06)  19 13.67 1.39 (0.84-2.17) 
Ischemic heart disease 
< 15 years <5 * 0.00 (0.00-3200)  13 14.18 0.92 (0.49-1.57)  13 14.18 0.92 (0.49-1.57) 
≥15 years <5 * 0.00 (0.00-2.86)  29 21.45 1.25 (0.91-1.94)  29 22.74 1.28 (0.85-1.83) 
Accident, Suicide and Violence 
< 15 years <5 * 4.89 (1.01-14) †  <5 * 0.58 (0.01-3.22)  <5 * 1.71 (0.47-4.37) 
≥15 years <5 * 1.95 (0.53-4.98)  <5 * 1.10 (0.23-3.21)  7 4.79 1.46 (0.59-3.01) 
            
SMR, Standardised mortality ratio; CI, Confidence Interval; Obs, Observed deaths; Exp, Expected deaths; N, Number of participants  
* In order to minimize the risk of disclosure of the identity of individual study participants, we have adhered to the rule of thumb 
suggested by the Office for National Statistics of suppressing all cell frequencies where the observed cell frequency is less than 5 
(“Review of the Dissemination of Health Statistics: Confidentiality Guidance: National Statistics; HMSO 2006”). 
† P<0.05 
 
 
 Table 5: Summary of key findings from all follow-up of the Lothian cohort 
Study 
No. 
patients Follow-up Time 
Statistical 
Measure Key Findings and comments 
Logan et al.11 653 Date of clinical 
diagnosis of CD to  
June 30, 1986 
(8,823 person years 
at risk, 115 deaths) 
Overall and 
cause-
specific 
SMRs 
 Mortality overall was 1.9-fold for CD patients than that of the general 
population. The SMR was similar in men and women.  
 10 deaths were directly attributable to CD, compared to 44 from 
malignancies (corresponding SMR of 3.0 fold for malignancies).  
 Only 4 deaths occurred in cases diagnosed in childhood (aged<15 years, 
total sample size of 292). All these deaths were from external causes. 
 Overall, there was a gradual decline in SMR with increased time from 
diagnosis. For 15+ years, there was an SMR of 1.2; however, this was 
based on just 11.64 expected deaths and was not statistically significant.  
Solaymani-
Dodaran et al.10  
*602 **Date of clinical 
diagnosis of CD or 
January 1, 1970 
(whichever was 
later) to  December 
31, 2004 
(14,926 person-
years, 195 deaths) 
Overall and 
cause-
specific 
SMRs 
 All analyses in this paper were presented separately for child (0-14 years) 
and adult (15+ years) diagnosed cases. The overall raised mortality risk 
was higher in childhood-diagnosed cases (SMR=2.6) than for adult-
diagnosed cases (SMR=1.6)  
 Among childhood-diagnosed cases there were 21 deaths, of which 7 were 
due to external causes (SMR=2.9) and 5 due to neoplasms (SMR=3.6). 
Both these increases were statistically significant.  
 Due to the increased follow-up, the expected number of deaths 15+ years 
following diagnosis had increased to 68.71. In childhood-diagnosed cases 
there was a raised risk 25+ years after diagnosis (SMR=3.5). For adult-
diagnosed cases, no corresponding risk was observed but the confidence 
interval was wide (SMR=1.26; 95% 0.86 to 1.77).  
Current study 602 **Date of clinical 
diagnosis of CD or 
January 1, 1970 
Overall and 
Cause-
 In the current study, the overall increase in mortality was 2.1-fold in 
childhood-diagnosed cases and 1.4-fold in adult-diagnosed cases. The 
 CD, Coeliac disease; SMR, Standardised mortality ratio; CI, Confidence Interval 
* The sample size reported in the paper was 625, however, the authors excluded 23 deaths (out of 218 deaths that had occurred in the 625 CD 
cases) that occurred before 1 Jan 1970 from the main analysis reported in the paper.  
**The survival analysis commenced in 1970 in the analysis presented in this paper, to circumvent the problem of survival bias and because 
population mortality estimates by cause were more reliable from this date onwards. 
(whichever was 
later) to October 20, 
2016 
(19,071 person 
years, 237 deaths) 
specific 
SMRs 
decrease in overall SMRs compared with the earlier reports reflects the 
decline in risk following increased time from diagnosis.  
 There were 32 deaths among childhood-diagnosed cases, of which the 
number of deaths from malignancy increased to 8 and the number from 
external causes remained at 7. However, the expected number of deaths 
from external causes only increased slightly compared with the previous 
report (2.67 vs. 2.39) as childhood-diagnosed participants are now at an age 
where deaths attributed to this cause are less common. 
 The expected number of deaths 15+ years following diagnosis has 
increased to 114.64. Among adult-diagnosed cases, the absence of an 
increased risk beyond 25 years reported previously remains but the 
confidence interval around this value has tightened considerably 
(SMR=0.97; (95% 0.74 to 1.24).   The equivalent SMR for childhood-
diagnosed cases was reduced in this updated follow-up (SMR=2.2) as the 
impact of deaths from external causes on this overall figure has been 
weakened.   
 There was a reduced risk of death from any malignancy more than 15 years 
after diagnosis in adult-diagnosed CD patients. Previously Grainge et al.17  
reported no change in malignancy incidence in this group compared with 
the general population 15 years after diagnosis. In the previous mortality 
report, cause-specific results only stratified time since diagnosis into <5 
years and 5+ years.  
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STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of 
case ascertainment and control selection. Give the rationale for the choice of cases 
and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of 
selection of participants 
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of 
controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there 
is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was 
addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of 
sampling strategy 
(e) Describe any sensitivity analyses 
Continued on next page
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Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and 
analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information 
on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of interest 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 
Case-control study—Report numbers in each exposure category, or summary measures of 
exposure 
Cross-sectional study—Report numbers of outcome events or summary measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and 
why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful 
time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 
analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity 
of analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, 
for the original study on which the present article is based 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org. 
 Appendix: Causes of death analysed and their corresponding ICD codes 
 
ICD Code 
Disease Group ICD 8 ICD 9 ICD 10 
Neoplasms 
   All malignant neoplasms 140-209 140-209 C00-97 
Malignant neoplasm of lymphoid, 
haematopoietic and related tissue 200-209 200-209 C81-96 
Malignant neoplasm of breast 174 174-175 C50 
§Malignant neoplasm of digestive 
organs 
150-151, 153-155, 
157-158 
150-151, 153-155, 
157-159 
C15-16, C18, 
C19-22, C25 
    Diseases of the circulatory system 
   Ischaemic heart disease 410-414 410-414 I20-25 
Cerebrovascular disease 430-438 430-438 I60-69 
    External causes of morbidity and mortality 
‡Accident E800-929, E940-946 E800-929 
V01-X59, Y85, 
Y86 
Intentional self-harm (suicide) E950-959 E950-959 X60-84, Y87.0 
Assault (violence) E960-969 E960-969 X85-Y09, Y87.1 
Event of undetermined intent  E980-989 E980-989 Y10-Y34, Y87.2 
    
ICD, International Classification of Diseases 
§Excludes malignant neoplasms of small intestine, gall bladder, other and ill-defined digestive organs 
‡Includes transport accidents, falls and poisoning 
 
